ArticleJTCVS techniques2026
Totally endoscopic port access for rheumatic mitral valve replacement: Clinical outcomes and a single surgeon's learning curve experience.
Article in JTCVS techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prior minimally invasive experience and the robotic mitral valve learning curve: a focused narrative review and the tactile-visual decoupling hypothesis.Journal of robotic surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study evaluates the safety and efficacy of totally endoscopic surgery for rheumatic mitral valve disease (RMVD) and analyzes the learning curve using cumulative sum control chart (CUSUM) and risk-adjusted (RA)-CUSUM failure models. Methods: From March 2018 to November 2023, 242 consecutive patients with RMVD underwent totally endoscopic surgery via three 5.5-mm trocars and a 3- to 4-cm working port. Optimized management for atrial fibrillation (AF) included (1) mitral valve replacement, (2) tricuspid valve repair, (3) AF ablation, and (4) left atrial reduction. CUSUM and RA-CUSUM failure analyses were used to evaluate the learning curve progression, and comparisons were made between different learning curve phases. Results: The median aortic crossclamp and cardiopulmonary bypass times were 98.5 (81-116) minutes and 178 (146-202) minutes, respectively, with a median follow-up of 37 months. Among 187 patients with long-standing persistent AF, 53 received optimized treatment, and a 91% AF-free rate was achieved at 1-year follow-up. In-hospital mortality occurred in 2 cases, attributable to intestinal infarction, and 1 late mortality resulted from massive intracranial hemorrhage. Major complications included 5 reoperations, 5 cases of severe unilateral pulmonary edema, and 4 cases of low cardiac output syndrome. CUSUM Conclusions: Totally endoscopic surgery for RMVD, including optimized AF management, is safe and feasible. Mastery of isolated endoscopic mitral valve replacement requires 86 cases to optimize aortic crossclamp time and 60 cases to effectively manage perioperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.